Slobodan Obradovic

By Slobodan Obradovic, Bela Balint and Zoran Trifunovic

Part of the book: Stem Cells in Clinic and Research

By Branislav Baskot, Igor Ivanov, Dragan Kovacevic, Slobodan Obradovic, Nenad Ratkovic and Miodrag Zivkovic

Part of the book: What Should We Know About Prevented, Diagnostic, and Interventional Therapy in Coronary Artery Disease

By Bela Balint, Slobodan Obradovic, Milena Todorovic, Mirjana Pavlovic and Biljana Mihaljevic

Part of the book: Stem Cell Biology in Normal Life and Diseases

By Stanko Petrovic, Slobodan Obradovic, Marijana Petrovic and Nemanja Rancic

Based on the role of platelets in inflammation and hemostasis it has been assumed that antiplatelet therapy could be beneficial for patients suffering from ulcerative colitis. Platelets present a link between inflammation and coagulation. They have more than 300 active mediators stored in their granules. Upon activation, platelet degranulate and release a lot of microparticles and mediators and interact with other immune and non-immune cells thereby amplifying inflammation. The most important parameters of platelet activation are P-selectin and CD40 ligand expressed on their surface upon activation, and their soluble forms presented in blood. Today, we have potent anti-platelet drugs that can inhibit platelet activation and degranulation, and thereby reduce inflammation. The most important drugs are P2Y12 receptor antagonists such as ticagrelor and clopidogrel and glycoprotein IIbIIIa inhibitors. Ticagrelor is an active drug and besides antiplatelet activity, it has bactericidal activity against Gram-positive strains and Clostridium difficile. Clopidogrel is a prodrug with less anti-inflammatory effect than ticagrelor and no proven bactericidal activity. Glycoprotein IIbIIIa inhibitors are very potent in reducing platelet aggregation but have lower anti-inflammatory potential than ticagrelor and clopidogrel.

Part of the book: Ulcerative Colitis